Home Our product

Our product

For more information about OFEV® (nintedanib), which has been approved for the treatment of IPF patients in Canada, the EU, Japan and the US,1-4 please visit the product website.

 

 

 

References: 
  1. Boehringer Ingelheim. OFEV® (nintedanib) approved in the EU for the treatment of IPF. Available at: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/19_january_2015_ipf.html. Accessed March 4, 2015.
  2. Boehringer Ingelheim. Boehringer Ingelheim’s OFEV® (nintedanib) approved by the FDA for the treatment of idiopathic pulmonary fibrosis Available at: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/16_october_2014.html. Accessed March 4, 2015.
  3. Boehringer Ingelheim (Canada). Health Canada approves OFEV® (nintedanib) for the treatment of idiopathic pulmonary fibrosis. Available at: http://www.boehringer-ingelheim.ca/en/news/press_releases/2015/06Jul2015111.html. Accessed July 21, 2015.
  4. PMDA. オフェブカプセル100mg/オフェブカプセル150mg - 650168_39990A7M1026_1_02. Available at: http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/650168_39990A7M1026_1_02. Accessed July 22, 2015.